Clinical Trial Update: IFM 99-02 Thalidomide in Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial IFM 99-02 evaluating thalidomide in multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalomid (thalidomide)

Snippet

Sponsor: University Hospital, Toulouse | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED